Effect of Hepatocellular Carcinoma on Mortality Among Individuals With Hepatitis B or Hepatitis C Infection in New York City, 2001–2012 See the full article here. Background. Hepatocellular carcinoma (HCC) is a complication of chronic hepatitis B and C virus (HBV and HCV) inf...
Publications
The NYC Department of Health and Mental Hygiene (DOHMH) examined anti-HCV and RNA testing performed by dialysis centres in NYC between 1 January 2014 and 31 December 2017 to assess HCV testing practices.
Evaluation of whether enrollment in Project INSPIRE was associated with differences in HCV treatment and cure compared with a demographically similar group not enrolled in the programme.
Project INSPIRE provides care coordination to HCV patients and a web‐based training program (telementoring) on disease management and treatment by HCV specialists to primary care providers inexperienced in HCV treatment.
The NYC Health Department recently released the 2018 version of City Health Information (CHI): Preventing, Identifying, and Managing Hepatitis B Virus Infection.
The NYC Health Department recently released the 2018 version of City Health Information (CHI): Diagnosing & Managing Hep C providing guidance to Primary Care Providers in hepatitis C screening, management and treatment.
The primary goals of the Manual are to increase advocates' knowledge about available HCV tests and treatments and to jumpstart discussions on advocacy strategies that can be used to open up affordable access for more people with HCV.
The American College of Physicians' High Value Care Task Force and the Centers for Disease Control and Prevention developed this article to present best practice statements for hepatitis B vaccination, screening, and linkage to care.
This study aims to validate algorithms designed to estimate treatment and cure of Hep C using RNA test results reported through routine surveillance.
On October 16, 2014, the fee-for-service (FFS) pharmacy program implemented clinical criteria for Hepatitis C Virus (HCV) drug therapy, as was recommended by the Drug Utilization Review Board (DURB) at the September 18, 2014 meeting. Included in this criteria were the following ...
